Ling Li

US Patent:

7754718, Jul 13, 2010

Filed:

May 2, 2005

Appl. No.:

11/579284

Inventors:

Hosup Yeo - Daegu, KR
David J. Austin - New York NY, US
Ling Li - Bellaire TX, US
Yung-chi Cheng - Woodbridge CT, US

Assignee:

Yale University - New Haven CT

International Classification:

A61K 31/502
C07D 237/26

US Classification:

514248, 544233

Abstract:

The present invention relates to novel antiviral helioxanthin analogs. These compounds may particularly be used alone or in combination with other drugs for the treatment of the following: hepadnaviruses, flaviviruses, herpesviruses and human immunodeficiency virus. In addition, compounds according to the present invention can be used to prevent or reduce the likelihood of the occurrence of tumors secondary to virus infection as well as other infections or disease states that are secondary to the virus infection.

US Patent:

7263132, Aug 28, 2007

Filed:

Oct 31, 2002

Appl. No.:

10/285269

Inventors:

Jyhchau Horng - Warren NJ, US
Ling Li - New Providence NJ, US

Assignee:

Mitsubishi Electric Research Laboratories, Inc. - Cambridge MA

International Classification:

H04B 7/02

US Classification:

375267, 375299, 375347

Abstract:

A method for transmitting a stream of data symbols in a multiple-input/multiple-output (MIMO) wireless communications system including Ntransmitting antennas. The stream of data symbols is first demultiplexed into M sub-streams, where M=N/2. Then, space-time transmit diversity encoding is applied to each sub-stream to generate a pair of transmit signals. Power is allocated dynamically to each transmit signal of each pair of transmit signals according to a corresponding feedback signal received from a receiver of the transmit signal. The feedback signal including a ratio of magnitude sums of channel coefficients for channels used for the transmit signals.

US Patent:

20220281844, Sep 8, 2022

Filed:

Aug 5, 2020

Appl. No.:

17/632811

Inventors:

- Princeton NJ, US
Kandhasamy Sarkunam - Hosur, IN
Ling Li - Pennington NJ, US
Lidet A. Negash - Plainsboro NJ, US
John Hynes - Washington Crossing PA, US

International Classification:

C07D 401/14
C07D 401/04
C07D 215/54
C07D 417/04
C07D 405/14
C07D 413/14
C07D 417/14
C07D 409/14
C07D 471/04
C07D 213/22
C07D 213/04
C07D 277/22
C07D 213/38

Abstract:

Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X is CRor N; Y is CRor N; Z is CRor N; provided that zero or 1 of X, Y, and Z is N; and R, R, R, R, R, R, and Rare define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

US Patent:

20220267348, Aug 25, 2022

Filed:

Jul 22, 2020

Appl. No.:

17/628976

Inventors:

- Princeton NJ, US
Ling Li - Pennington NJ, US
Hong Wu - New Hope PA, US
John Hynes - Washington Crossing PA, US

International Classification:

C07D 495/04
C07D 513/04

Abstract:

Disclosed are compounds of Formula (I) [INSERT CHEMICAL STRUCTURE HERE] (I) or a salt or prodrug thereof, wherein: X is CR4 or N; and R, R, R, R, and n are defined herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

US Patent:

20210147357, May 20, 2021

Filed:

Aug 8, 2018

Appl. No.:

16/636670

Inventors:

- Princeton NJ, US
Ling Li - Pennington NJ, US
John L. Gilmore - Yardley PA, US

International Classification:

C07D 207/16

Abstract:

Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is —CH— or —C(O)—; Ris —OH or —OP(O)(OH); L is a bond, —CH—, or —C(O)—; Ris n-Calkyl; each Ris independently selected from Cl and —CH; and n is zero, 1, or 2; provided that if X is —CH—, then L is —CH— or —C(O)—. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor SlP, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

US Patent:

20210147361, May 20, 2021

Filed:

Aug 8, 2018

Appl. No.:

16/636662

Inventors:

- Princeton NJ, US
Ling Li - Pennington NJ, US

International Classification:

C07D 213/53
C07D 207/12
C07D 211/40
C07D 211/96
A61P 37/06

Abstract:

Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is CH or N; Y is CH or N; Ris —OH or —OP(O)(OH); Lis —CR═N—O—CRR— or CRR—O—N═CR; Lis a bond, —C(O)—, or S(O)—; and R, R, R, m, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

US Patent:

20200291069, Sep 17, 2020

Filed:

Oct 2, 2018

Appl. No.:

16/753666

Inventors:

- Princeton NJ, US
Martin Patrick ALLEN - Flemington NJ, US
Ling LI - Pennington NJ, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07K 7/56

Abstract:

The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

US Patent:

20200062777, Feb 27, 2020

Filed:

May 10, 2018

Appl. No.:

16/612478

Inventors:

- Princeton NJ, US
Ling Li - Pennington NJ, US
Lidet A. Negash - Plainsboro NJ, US
John Hynes - Washington Crossing PA, US

International Classification:

C07D 495/04
C07D 409/12

Abstract:

Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X is CRor N; Y is CRor N; provided that only one of X and Y is N; (R1) is: or; wherein R, R, R, R, R, and Rare define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.